Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
Tuesday, September 08, 2020 10:31:23 AM
-Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC pa...
Read the whole news ALBO - Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC
Recent ALBO News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:33:48 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM